Naito Atsushi, Iwamoto Kazuya, Ohtsuka Masahisa, Imasato Mitsunobu, Inui Motoharu, Zenitani Shigetake, Wada Ryohei, Nakahara Yujiro, Mikamori Manabu, Furukawa Kenta, Moon Jeongho, Asaoka Tadafumi, Kishi Kentaro, Akamatsu Hiroki
Dept. of Surgery, Osaka Police Hospital.
Gan To Kagaku Ryoho. 2020 Dec;47(13):2104-2106.
A phase-Ⅱtrial of TAS-102 plus bevacizumab(Bev)combination therapy showed a progression-free survival(PFS)of 3.7-4.6 months. Here, we report 12 cases of unresectable advanced recurrent colorectal cancer treated with TAS-102 plus Bev therapy at our hospital between June 2017 and February 2020. The median PFS was 6 months(2-12). Adverse events greater than Grade 3 were neutropenia(33.3%), febrile neutropenia(8.3%), thrombocytopenia(8.3%), and vomiting (8.3%). The frequency of non-hematotoxicity was low. In conclusion, the TAS-102 plus Bev therapy may be a useful option for the late-line treatment of unresectable advanced recurrent colorectal cancer.
一项TAS-102联合贝伐单抗（Bev）的Ⅱ期试验显示无进展生存期（PFS）为3.7至4.6个月。在此，我们报告了2017年6月至2020年2月期间在我院接受TAS-102联合Bev治疗的12例不可切除的晚期复发性结直肠癌患者。中位PFS为6个月（2至12个月）。3级以上不良事件为中性粒细胞减少（33.3%）、发热性中性粒细胞减少（8.3%）、血小板减少（8.3%）和呕吐（8.3%）。非血液毒性的发生率较低。总之，TAS-102联合Bev治疗可能是不可切除的晚期复发性结直肠癌晚期治疗的一个有用选择。
